FR2807767B1 - Anticorps monoclonaux anti-d - Google Patents

Anticorps monoclonaux anti-d

Info

Publication number
FR2807767B1
FR2807767B1 FR0004685A FR0004685A FR2807767B1 FR 2807767 B1 FR2807767 B1 FR 2807767B1 FR 0004685 A FR0004685 A FR 0004685A FR 0004685 A FR0004685 A FR 0004685A FR 2807767 B1 FR2807767 B1 FR 2807767B1
Authority
FR
France
Prior art keywords
mab
monoclonal antibodies
effector cells
antibody
adcc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0004685A
Other languages
English (en)
French (fr)
Other versions
FR2807767A1 (fr
Inventor
Roland Beliard
Dominique Bourel
Arnaud Glacet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8849165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2807767(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LFB SA filed Critical LFB SA
Priority to FR0004685A priority Critical patent/FR2807767B1/fr
Priority to DK10180551.3T priority patent/DK2341078T3/en
Priority to AT01927974T priority patent/ATE419276T2/de
Priority to US10/257,477 priority patent/US7579170B2/en
Priority to DK04028814.4T priority patent/DK1518864T4/da
Priority to EP01927974.4A priority patent/EP1272527B2/fr
Priority to ES04028814T priority patent/ES2525762T5/es
Priority to EP15173391.2A priority patent/EP2947099A1/fr
Priority to CA2406033A priority patent/CA2406033C/fr
Priority to EP04028814.4A priority patent/EP1518864B2/fr
Priority to JP2001575651A priority patent/JP5192625B2/ja
Priority to AU2001254858A priority patent/AU2001254858B2/en
Priority to DK01927974.4T priority patent/DK1272527T4/da
Priority to ES01927974T priority patent/ES2320412T5/es
Priority to PCT/FR2001/001127 priority patent/WO2001077181A2/fr
Priority to DE60137210T priority patent/DE60137210D1/de
Priority to EP10180551.3A priority patent/EP2341078B1/fr
Priority to ES10180551.3T priority patent/ES2601241T3/es
Publication of FR2807767A1 publication Critical patent/FR2807767A1/fr
Application granted granted Critical
Publication of FR2807767B1 publication Critical patent/FR2807767B1/fr
Priority to US11/039,877 priority patent/US7931895B2/en
Priority to US11/517,525 priority patent/US7541029B2/en
Priority to AU2007202060A priority patent/AU2007202060B2/en
Priority to US12/502,915 priority patent/US8153124B2/en
Priority to US12/502,911 priority patent/US8124078B2/en
Priority to US12/502,920 priority patent/US8178093B2/en
Priority to AU2010257417A priority patent/AU2010257417B2/en
Priority to US13/077,644 priority patent/US8685725B2/en
Priority to US13/436,114 priority patent/US8409572B2/en
Priority to US13/443,532 priority patent/US8357370B2/en
Priority to JP2012128846A priority patent/JP5722279B2/ja
Priority to JP2012128847A priority patent/JP5837859B2/ja
Priority to JP2012128845A priority patent/JP5722278B2/ja
Priority to JP2013103336A priority patent/JP5788432B2/ja
Priority to US14/157,061 priority patent/US9708409B2/en
Priority to US14/617,836 priority patent/US9718889B2/en
Priority to US14/676,508 priority patent/US9718890B2/en
Priority to JP2015163589A priority patent/JP6124958B2/ja
Priority to JP2015163588A priority patent/JP2015221827A/ja
Priority to JP2016199815A priority patent/JP2017012199A/ja
Priority to US15/616,596 priority patent/US10081683B2/en
Priority to JP2017174012A priority patent/JP2017214427A/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR0004685A 2000-04-12 2000-04-12 Anticorps monoclonaux anti-d Expired - Lifetime FR2807767B1 (fr)

Priority Applications (40)

Application Number Priority Date Filing Date Title
FR0004685A FR2807767B1 (fr) 2000-04-12 2000-04-12 Anticorps monoclonaux anti-d
JP2001575651A JP5192625B2 (ja) 2000-04-12 2001-04-12 抗ｄモノクローナル抗体
DK01927974.4T DK1272527T4 (da) 2000-04-12 2001-04-12 Fremstilling af antistoffer med adcc via cd16 og især monoklonale anti-rhesus d-antistoffer
US10/257,477 US7579170B2 (en) 2000-04-12 2001-04-12 Method for preparing monoclonal antibodies capable of activating effector cells expressing FCγRIII
DK04028814.4T DK1518864T4 (da) 2000-04-12 2001-04-12 Sammensætning af antistoffer med høj ADCC
EP01927974.4A EP1272527B2 (fr) 2000-04-12 2001-04-12 Preparation d'anticorps ayant une adcc via le cd16, notamment des anticorps monoclonaux anti rhesus d
ES04028814T ES2525762T5 (es) 2000-04-12 2001-04-12 Composición de anticuerpos con alta ADCC
EP15173391.2A EP2947099A1 (fr) 2000-04-12 2001-04-12 Anticorps presentant une activite adcc amelioree
CA2406033A CA2406033C (fr) 2000-04-12 2001-04-12 Anticorps monoclonaux anti-d
EP04028814.4A EP1518864B2 (fr) 2000-04-12 2001-04-12 Composition d'anticorps à haute ADCC
DK10180551.3T DK2341078T3 (en) 2000-04-12 2001-04-12 Antibodies with improved ADCC activity
AU2001254858A AU2001254858B2 (en) 2000-04-12 2001-04-12 Anti-D monoclonal antibodies
AT01927974T ATE419276T2 (de) 2000-04-12 2001-04-12 Verfahren von antikörper mit adcc via cd16, z.b. monoklonale antikörper gegen rhesus d
ES01927974T ES2320412T5 (es) 2000-04-12 2001-04-12 Preparación de anticuerpos que tienen una ADCC a través del CD16, en particular de los anticuerpos monoclonales anti-Rhesus D
PCT/FR2001/001127 WO2001077181A2 (fr) 2000-04-12 2001-04-12 Anticorps monoclonaux anti-rhesus d
DE60137210T DE60137210D1 (de) 2000-04-12 2001-04-12 Verfahren von antikörper mit adcc via cd16, z.b. monoklonale antikörper gegen rhesus d
EP10180551.3A EP2341078B1 (fr) 2000-04-12 2001-04-12 Anticorps présentant une activité ADCC améliorée
ES10180551.3T ES2601241T3 (es) 2000-04-12 2001-04-12 Anticuerpo que presenta una actividad ADCC mejorada
US11/039,877 US7931895B2 (en) 2000-04-12 2005-01-24 Monoclonal antibodies with enhanced ADCC function
US11/517,525 US7541029B2 (en) 2000-04-12 2006-09-08 Anti-rhesus D monoclonal antibodies
AU2007202060A AU2007202060B2 (en) 2000-04-12 2007-05-08 Anti-D monoclonal antibodies
US12/502,911 US8124078B2 (en) 2000-04-12 2009-07-14 Method for treating idiopathic thrombocytopenic purpura using monoclonal antibodies
US12/502,915 US8153124B2 (en) 2000-04-12 2009-07-14 Method for treating cancer using monoclonal antibodies
US12/502,920 US8178093B2 (en) 2000-04-12 2009-07-14 Method for treating infectious disease using monoclonal antibodies
AU2010257417A AU2010257417B2 (en) 2000-04-12 2010-12-23 Anti-D monoclonal antibodies
US13/077,644 US8685725B2 (en) 2000-04-12 2011-03-31 Monoclonal antibodies with enhanced ADCC function
US13/436,114 US8409572B2 (en) 2000-04-12 2012-03-30 Monoclonal antibodies with enhanced ADCC function
US13/443,532 US8357370B2 (en) 2000-04-12 2012-04-10 Anti-D monoclonal antibodies
JP2012128845A JP5722278B2 (ja) 2000-04-12 2012-06-06 抗ｄモノクローナル抗体
JP2012128847A JP5837859B2 (ja) 2000-04-12 2012-06-06 抗ｄモノクローナル抗体
JP2012128846A JP5722279B2 (ja) 2000-04-12 2012-06-06 抗ｄモノクローナル抗体
JP2013103336A JP5788432B2 (ja) 2000-04-12 2013-05-15 抗ｄモノクローナル抗体
US14/157,061 US9708409B2 (en) 2000-04-12 2014-01-16 Monoclonal antibodies with enhanced ADCC function
US14/617,836 US9718889B2 (en) 2000-04-12 2015-02-09 Monoclonal antibodies with enhanced ADCC function
US14/676,508 US9718890B2 (en) 2000-04-12 2015-04-01 Monoclonal antibodies with enhanced ADCC function
JP2015163588A JP2015221827A (ja) 2000-04-12 2015-08-21 抗ｄモノクローナル抗体
JP2015163589A JP6124958B2 (ja) 2000-04-12 2015-08-21 抗ｄモノクローナル抗体
JP2016199815A JP2017012199A (ja) 2000-04-12 2016-10-11 抗ｄモノクローナル抗体
US15/616,596 US10081683B2 (en) 2000-04-12 2017-06-07 Monoclonal antibodies with enhanced ADCC function
JP2017174012A JP2017214427A (ja) 2000-04-12 2017-09-11 抗ｄモノクローナル抗体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0004685A FR2807767B1 (fr) 2000-04-12 2000-04-12 Anticorps monoclonaux anti-d

Publications (2)

Publication Number Publication Date
FR2807767A1 FR2807767A1 (fr) 2001-10-19
FR2807767B1 true FR2807767B1 (fr) 2005-01-14

Family

ID=8849165

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0004685A Expired - Lifetime FR2807767B1 (fr) 2000-04-12 2000-04-12 Anticorps monoclonaux anti-d

Country Status (11)

Country Link
US (13) US7579170B2 (https=)
EP (4) EP2341078B1 (https=)
JP (9) JP5192625B2 (https=)
AT (1) ATE419276T2 (https=)
AU (3) AU2001254858B2 (https=)
CA (1) CA2406033C (https=)
DE (1) DE60137210D1 (https=)
DK (3) DK1272527T4 (https=)
ES (3) ES2601241T3 (https=)
FR (1) FR2807767B1 (https=)
WO (1) WO2001077181A2 (https=)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2463879C (en) * 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
FR2844521B1 (fr) * 2002-09-13 2004-12-24 Lab Francais Du Fractionnement Mesure de la production de cytokines comme marqueur d'activation de cellules effectrices
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
FR2844520B1 (fr) * 2002-09-13 2006-06-09 Lab Francais Du Fractionnement Utilisation d'un anticorps induisant la secretion de cytokines en therapie
WO2004024768A2 (fr) * 2002-09-13 2004-03-25 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps induisant la production de cytokines
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
CA2520820A1 (en) * 2003-04-03 2004-10-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Therapeutic products with enhanced ability to immunomodulate cell functions
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
FR2861078B1 (fr) * 2003-10-16 2007-09-21 Lab Francais Du Fractionnement NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
GB0324368D0 (en) * 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
FR2861080B1 (fr) * 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
FR2861079B1 (fr) * 2003-10-20 2007-09-28 Lab Francais Du Fractionnement Utilisation de cations metalliques divalents pour l'amelioration de l'activite fonctionnelle des anticorps.
EP1720570A4 (en) * 2004-01-26 2008-09-03 Cangene Corp TREATMENT OF DENGUE H MORRAGIC FIUR
ES2641832T3 (es) 2004-05-24 2017-11-14 Ibis Biosciences, Inc. Espectrometría de masas con filtración de iones selectiva por establecimiento de umbrales digitales
EP1941275B1 (en) * 2005-09-29 2013-07-24 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
SI1945665T1 (sl) * 2005-10-21 2012-03-30 Genzyme Corp Terapevtska sredstva na osnovi protiteles s povečano ADCC aktivnostjo
KR20140133958A (ko) * 2005-10-21 2014-11-20 엘에프비 유에스에이, 인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법
FR2895086B1 (fr) * 2005-12-16 2012-10-05 Lab Francais Du Fractionnement Potentialisation de l'apoptose par des anticorps monoclonaux
US20090175886A1 (en) * 2006-01-17 2009-07-09 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
EP1933137A1 (fr) * 2006-12-15 2008-06-18 Glycode Méthode d'investigation de la réponse à un traitement par un anticorps monoclonal
DE602007013068D1 (de) * 2006-09-13 2011-04-21 Glycode Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper
EP1918304A1 (en) * 2006-11-02 2008-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II)
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20110217317A1 (en) * 2008-08-26 2011-09-08 Symphogen A/S Treatment of thrombocytopenia
CA2746350C (en) 2008-12-31 2018-06-12 Bharat Serums And Vaccines Ltd. Anti-rhd monoclonal antibodies
WO2010099186A1 (en) * 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Her2 antibody compositions
FR2942799B1 (fr) 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
CA2756244A1 (en) * 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
EP2417164A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-2/anti-c-met antibodies
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CA2769595A1 (en) 2009-08-14 2011-02-17 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
US8883496B2 (en) 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice
CA2784953C (en) 2009-12-21 2018-05-22 Regeneron Pharmaceuticals, Inc. Humanized fc.gamma.r mice
RS54795B1 (sr) 2009-12-22 2016-10-31 Roche Glycart Ag Anti-her3 antitela i njihova korišćenja
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
RU2585489C2 (ru) 2010-04-27 2016-05-27 Рош Гликарт Аг КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR
JP5956982B2 (ja) 2010-05-27 2016-07-27 メルク・シャープ・エンド・ドーム・コーポレイション 改善された特性を有する抗体の製造方法
JP2013535198A (ja) 2010-07-30 2013-09-12 グリコド 哺乳類のグリコシル化経路を有する酵母人工染色体
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012080389A1 (en) 2010-12-16 2012-06-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
FR2971250A1 (fr) 2011-02-07 2012-08-10 Univ Nantes Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
AU2012258907A1 (en) 2011-05-25 2013-11-07 Merck Sharp & Dohme Corp. Method for preparing Fc-containing polypeptides having improved properties
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
TWI687439B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
CN103827134A (zh) * 2011-07-20 2014-05-28 泽普泰恩股份有限公司 多肽分离方法
JP6041882B2 (ja) 2011-09-23 2016-12-14 ロシュ グリクアート アーゲー 二重特異性抗ｅｇｆｒ／抗ｉｇｆ−１ｒ抗体
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
FR2981946B1 (fr) * 2011-10-28 2015-02-20 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (yb2/0)
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
KR20230143201A (ko) 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
EP3756686A1 (en) 2012-11-02 2020-12-30 TG Therapeutics Inc. Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
US20160185847A1 (en) 2012-12-17 2016-06-30 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
FR3003172B1 (fr) * 2013-03-15 2017-12-08 Lab Francais Du Fractionnement Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
FR3003171B1 (fr) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
MX366910B (es) 2013-03-15 2019-07-30 Janssen Biotech Inc Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
JP2016538283A (ja) 2013-11-13 2016-12-08 ザイムワークス，インコーポレイテッド Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
AU2014357292B2 (en) 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
CN111690052B (zh) 2014-04-08 2024-06-04 瑞泽恩制药公司 具有人源化FC-γ受体的非人动物
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
EP3613433B1 (en) 2014-05-30 2022-01-05 Shanghai Henlius Biotech, Inc. Anti-epidermal growth factor receptor (egfr) antibodies
WO2016014595A2 (en) * 2014-07-21 2016-01-28 Bloodworks Antibodies that recognize red blood cell antigens
PH12017500442B1 (en) 2014-09-09 2023-05-24 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
CA2961950A1 (en) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2016082044A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
CN107406506A (zh) 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
EP3091033A1 (en) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
EA201792546A1 (ru) 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
IL256242B2 (en) 2015-06-22 2024-09-01 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3423491A1 (en) 2016-03-01 2019-01-09 H. Hoffnabb-La Roche Ag Obinutuzumab variants having altered cell death induction
EP3463318A4 (en) 2016-05-27 2020-01-01 TG Therapeutics Inc. COMBINATION OF ANTI-CD20-ANTIBODIES, P13-KINASE-DELTA-SELECTIVE INHIBITOR AND BTK-INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE B-CELL DISORDERS
EP3257866A1 (en) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
FR3053688B1 (fr) 2016-07-06 2026-05-01 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Mutants fc a activite fonctionnelle amelioree
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
WO2018049263A1 (en) 2016-09-09 2018-03-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
CN109890417A (zh) 2016-10-28 2019-06-14 东丽株式会社 癌的治疗和/或预防用药物组合物
FR3064007A1 (fr) 2017-03-20 2018-09-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps pour le traitement de cancers
US20200148785A1 (en) * 2017-03-29 2020-05-14 Glycotope (GmbH) Pd-l1 and ta-muc1 antibodies
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
EP4640703A3 (en) 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
IL277049B2 (en) 2018-03-13 2024-02-01 Zymeworks Bc Inc Conjugates of biparatopic anti-HER2 antibody and drug and methods of use
IL314733A (en) 2018-03-26 2024-10-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
AU2019242520B2 (en) 2018-03-30 2026-02-26 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
PL237868B1 (pl) 2018-04-04 2021-06-14 Gdanski Univ Medyczny Mutanty punktowe czynnika B oraz białka C2 do zastosowania do wzmacniania aktywności cytotoksycznej przeciwciał w leczeniu chorób nowotworowych
KR102259473B1 (ko) 2018-08-10 2021-06-02 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
SG11202107941TA (en) 2019-01-23 2021-08-30 Encefa Cd31 competitors and uses thereof
EP4696320A2 (en) 2019-05-15 2026-02-18 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibody
CN110320352A (zh) * 2019-07-25 2019-10-11 上海轩锋生物科技有限公司 基于抗体依赖的细胞介导细胞毒性的抗体效价检测方法
WO2021155295A1 (en) 2020-01-31 2021-08-05 The Cleveland Clinic Foundation Anti-müllerian hormone receptor 2 antibodies and methods of use
CA3175137A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3175277A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4119159A4 (en) 2020-03-12 2024-03-27 Toray Industries, Inc. MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
KR20220152309A (ko) 2020-03-12 2022-11-15 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
WO2021182574A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び／又は予防のための医薬品
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US20240279321A1 (en) 2021-06-18 2024-08-22 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE
US20250228937A1 (en) 2021-06-23 2025-07-17 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
MX2023014498A (es) 2021-06-23 2024-01-25 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer.
CN117693363A (zh) 2021-07-27 2024-03-12 东丽株式会社 用于癌的治疗和/或预防的药品
KR20240041917A (ko) 2021-07-27 2024-04-01 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
WO2023008461A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び／又は予防のための医薬品
CN118119409A (zh) 2021-09-03 2024-05-31 东丽株式会社 癌的治疗和/或预防用药物组合物
PL4401842T3 (pl) 2021-09-16 2025-11-24 Aboleris Pharma Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
EP4548932A1 (en) 2022-06-30 2025-05-07 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
JPWO2024043258A1 (https=) 2022-08-24 2024-02-29
WO2024043257A1 (ja) 2022-08-24 2024-02-29 東レ株式会社 癌の治療及び／又は予防のための医薬品
AU2023329558A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20250053841A (ko) 2022-08-30 2025-04-22 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
AU2023334696A1 (en) 2022-08-30 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
MX2025006330A (es) 2022-12-23 2025-07-01 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer
AU2024221322A1 (en) 2023-02-17 2025-07-03 Apogee Therapeutics, Inc. Antibodies that bind interleukin 4 receptor alpha and methods of use
AU2024246833A1 (en) 2023-03-31 2025-09-25 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CN121793988A (zh) 2023-09-13 2026-04-03 东丽株式会社 癌的治疗、预防和/或诊断用药物组合物
WO2025137523A2 (en) 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical formulations of antibodies that bind interleukin 13
WO2025137410A1 (en) 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine
WO2025255353A1 (en) 2024-06-06 2025-12-11 Apogee Therapeutics, Inc. Dosage and administration of an anti-ox40l antibody
WO2025264960A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind ox40l
WO2025264972A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-4r alpha and antibodies that bind
WO2026080829A1 (en) 2024-10-10 2026-04-16 Apogee Therapeutics, Inc. Methods of administering antibodies that bind interleukin 13
WO2026085417A2 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
WO2026085415A1 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind tslp in combination with hyaluronidase or a variant thereof
WO2026085419A2 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind il-13 in combination with hyaluronidase or a variant thereof
WO2026085414A1 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind tslp and antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA406033A (en) 1942-07-14 American Can Company Product packing apparatus
GB1382265A (en) 1971-12-03 1975-01-29 Ml Aviation Co Ltd Transporters
JPS56101171A (en) 1980-01-16 1981-08-13 Fuji Xerox Co Ltd Separation failure detector for transfer paper
EP0043718B1 (en) 1980-07-07 1984-11-28 National Research Development Corporation Improvements in or relating to cell lines
WO1985002413A1 (en) 1983-11-28 1985-06-06 The Board Of Trustees Of The Leland Stanford Jr. U HUMAN MONOCLONAL ANTIBODY AGAINST Rh(D) ANTIGEN AND ITS USES
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8610106D0 (en) 1986-04-25 1986-05-29 Central Blood Lab Authority Human igm-producing heterohybridoma
FR2600076A1 (fr) 1986-06-12 1987-12-18 Fond Ctre Nal Transfusion Milieu de culture comportant de l'albumine humaine, procede de preparation d'un produit injectable a partir de ce milieu, produit obtenu et son utilisation, composition obtenue
JPS6350710A (ja) 1986-08-21 1988-03-03 Koputeitsuku:Kk 光測定装置
GB8722018D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
GB8722020D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
GB8722019D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
ES2100892T3 (es) * 1989-09-15 1997-07-01 Tanox Biosystems Inc Tratamiento de enfermedades autoinmunitarias.
FR2653561A1 (fr) * 1989-10-19 1991-04-26 Fondation Nale Transfusion San Hetero-anticorps anti-rhd et composition pharmaceutique les contenant.
GB8925590D0 (en) 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
US5272070A (en) * 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
US5665569A (en) 1991-08-22 1997-09-09 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
US5811517A (en) 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
BR9305557A (pt) 1992-06-26 1997-03-25 Aetsrn Anticorpos monoclonais humanos anti Rhesus-D e composiçao farmacêutica que os contém
JP3565572B2 (ja) * 1992-09-07 2004-09-15 協和醗酵工業株式会社 ヒト化抗体
AU669379B2 (en) * 1992-09-07 1996-06-06 Kyowa Hakko Kirin Co., Ltd. Humanized antibodies
DE69419721T2 (de) 1993-01-12 2000-04-27 Biogen, Inc. Rekombinante anti-vla4 antikörpermoleküle
ATE238420T1 (de) 1993-08-24 2003-05-15 Nissin Food Products Ltd Rekombinanter humanisierter antikörper gegen menschlichen immunschwächevirus
FR2724182B1 (fr) 1994-09-02 1996-12-13 Pasteur Institut Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
ES2233974T3 (es) * 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
RU2094462C1 (ru) 1995-11-14 1997-10-27 Оловникова Наталья Ивановна Моноклональный иммуноглобулин человека класса iggi против антигена d системы резус
AU1672097A (en) * 1996-02-15 1997-09-02 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody that recognizes antigens present on the surface of endothelial cell of tumor vessel
WO1997045141A1 (en) 1996-05-31 1997-12-04 Sankyo Company, Limited Remedy for autoimmune diseases
JPH10212247A (ja) * 1996-05-31 1998-08-11 Sankyo Co Ltd 自己免疫疾患治療剤
AU722127B2 (en) 1996-06-24 2000-07-20 Zlb Behring Ag Polypeptides capable of forming antigen binding structures with specificity for the rhesus D antigens, the DNA encoding them and the process for their preparation and use
JPH1080276A (ja) * 1996-07-19 1998-03-31 Mitsui Petrochem Ind Ltd バイセクト糖鎖調節法
JPH10112531A (ja) 1996-08-13 1998-04-28 Hitachi Ltd 半導体集積回路装置の製造方法
JP4550947B2 (ja) * 1997-03-19 2010-09-22 協和発酵キリン株式会社 ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体
US6682928B2 (en) * 1997-12-02 2004-01-27 Medarex, Inc. Cells expressing anti-Fc receptor binding components
DK1071700T3 (da) * 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
JP2000005908A (ja) 1998-06-18 2000-01-11 Sony Corp 保持具、加工装置および加工方法
CA2704600C (en) * 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
DE60044858D1 (de) 1999-10-26 2010-09-30 Stichting Dienst Landbouwkundi Säugetierartige Glykosylierung in Pflanzen
ATE402192T1 (de) 2000-03-03 2008-08-15 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20060034829A1 (en) * 2001-12-27 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
WO2005014651A1 (ja) * 2003-08-11 2005-02-17 Chugai Seiyaku Kabushiki Kaisha 糖鎖改変抗hm1.24抗体
US7150443B2 (en) 2005-01-18 2006-12-19 Mills Douglas W Control valve for nitrous oxide injection system
WO2007028106A2 (en) * 2005-08-31 2007-03-08 Centocor, Inc. Host cell lines for production of antibody constant region with enhanced effector function
WO2009104055A1 (en) 2008-02-18 2009-08-27 Freescale Semiconductor, Inc. Mixer circuit

Also Published As

Publication number Publication date
JP2012191938A (ja) 2012-10-11
US20030175969A1 (en) 2003-09-18
AU2007202060A1 (en) 2007-05-31
JP5722279B2 (ja) 2015-05-20
US8685725B2 (en) 2014-04-01
DK1518864T3 (da) 2015-01-12
JP6124958B2 (ja) 2017-05-10
EP1272527A2 (fr) 2003-01-08
JP5788432B2 (ja) 2015-09-30
FR2807767A1 (fr) 2001-10-19
US20120259095A1 (en) 2012-10-11
JP5192625B2 (ja) 2013-05-08
EP1518864B2 (fr) 2019-10-16
ES2320412T5 (es) 2019-02-13
US8153124B2 (en) 2012-04-10
US20110223658A1 (en) 2011-09-15
US8357370B2 (en) 2013-01-22
CA2406033C (fr) 2014-05-27
EP1518864A2 (fr) 2005-03-30
CA2406033A1 (fr) 2001-10-18
JP2017012199A (ja) 2017-01-19
US8178093B2 (en) 2012-05-15
EP1272527B2 (fr) 2018-08-29
EP2341078B1 (fr) 2016-08-10
DK1272527T4 (da) 2019-01-02
AU5485801A (en) 2001-10-23
US7541029B2 (en) 2009-06-02
ES2601241T3 (es) 2017-02-14
EP2947099A1 (fr) 2015-11-25
JP5722278B2 (ja) 2015-05-20
US20120258096A1 (en) 2012-10-11
AU2010257417A1 (en) 2011-01-20
US20180002442A1 (en) 2018-01-04
DK1272527T3 (da) 2009-05-04
JP2015221827A (ja) 2015-12-10
US8124078B2 (en) 2012-02-28
US20150152189A1 (en) 2015-06-04
US20110059073A1 (en) 2011-03-10
US20110052571A1 (en) 2011-03-03
JP2015211696A (ja) 2015-11-26
US20110059072A1 (en) 2011-03-10
JP2013155198A (ja) 2013-08-15
JP2012193185A (ja) 2012-10-11
US20070009522A1 (en) 2007-01-11
US9718890B2 (en) 2017-08-01
DK2341078T3 (en) 2016-11-28
ATE419276T2 (de) 2009-01-15
US20140162356A1 (en) 2014-06-12
US10081683B2 (en) 2018-09-25
US20050249722A1 (en) 2005-11-10
EP1518864A3 (fr) 2009-07-22
WO2001077181A3 (fr) 2002-03-07
US9718889B2 (en) 2017-08-01
DE60137210D1 (de) 2009-02-12
JP5837859B2 (ja) 2015-12-24
ES2525762T5 (es) 2020-06-26
DK1518864T4 (da) 2020-01-27
US9708409B2 (en) 2017-07-18
EP2341078A3 (fr) 2011-12-21
ES2525762T3 (es) 2014-12-30
US8409572B2 (en) 2013-04-02
JP2012193184A (ja) 2012-10-11
ES2320412T3 (es) 2009-05-22
US7931895B2 (en) 2011-04-26
US20150266972A1 (en) 2015-09-24
EP2341078A2 (fr) 2011-07-06
JP2003534781A (ja) 2003-11-25
AU2007202060B2 (en) 2010-10-14
JP2017214427A (ja) 2017-12-07
WO2001077181A2 (fr) 2001-10-18
AU2001254858B2 (en) 2001-10-23
EP1518864B1 (fr) 2014-10-08
US7579170B2 (en) 2009-08-25
AU2010257417B2 (en) 2012-04-05
EP1272527B1 (fr) 2008-12-31

Similar Documents

Publication Publication Date Title
ES2525762T3 (es) Composición de anticuerpos con alta ADCC
WO2004058797A3 (en) Human monoclonal antibodies against interleukin 8 (il-8)
WO2004045512A3 (en) Human monoclonal antibodies against cd25
CA2023894C (en) Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulins
WO2003040169A3 (en) Human monoclonal antibodies to dendritic cells
WO2004035607A3 (en) Human monoclonal antibodies against cd20
CA2380783A1 (en) Human monoclonal antibodies to prostate specific membrane antigen
IL160358A0 (en) Human antibodies specific for interleukin 15 (il-15)
WO2002100348A3 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
WO2004076620A3 (en) Human antibodies specific for interleukin 15 (il-15)
WO2004043989A3 (en) Human monoclonal antibodies to heparanase
WO2001085798A3 (en) Human monoclonal antibodies to dendritic cells
ATE208820T1 (de) Humanisierte antikoerper
WO2003064606A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
CA2065414A1 (en) Treatment of autoimmune disease
AU2002310996A1 (en) Immunoconjugates made of egg-yolk antibodies (igy), production and use thereof in diagnoses and therapy
Leibiger et al. Glycosylation analysis of a polyreactive human monoclonal IgG antibody derived from a human-mouse heterohybridoma
EP0155172A3 (en) Anti-human lung cancer monoclonal antibodies
Donadel et al. Human polyreactive and monoreactive antibodies: effect of glycosylation antigen binding
Björklund et al. Characterisation of recombinant human IgE-Fc fragments expressed in baculovirus-infected insect cells
AU2004283925A1 (en) Use of metallic cations to improve functional activity of antibodies

Legal Events

Date Code Title Description
TP Transmission of property
TP Transmission of property

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES , FR

Effective date: 20130903

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20